Merck is making a $300 million move to acquire Immune Design, developers of a midphase immunotherapy for non-Hodgkin’s lymphoma, as well as vaccines for respiratory syncytial virus and peanut allergies.

Rutgers University scientists have made a surprising discovery about how wings form in fruit flies, disrupting long-held beliefs related to organ growth. They believe the finding could lead to improved methods for diagnosing and treating human genetic diseases.

Pfizer’s neuroscience spinoff, Cerevel Therapeutics, is bringing on Otsuka’s Raymond Sanchez, M.D., to serve as its new chief medical officer and take forward development of its late-stage programs for Parkinson’s disease and epilepsy into phase 3.

Because not all patients respond to anti-PD-1/L1 therapies, researchers are exploring new ways to improve their efficacy. Now, a team led by Cedars-Sinai Medical Center scientist has pinpointed Sprycel, a popular blood cancer drug by Bristol-Myers Squibb, as a potential booster.

Vical has stopped a phase 2 trial of antifungal VL-2397 and outlined plans to lay off employees. The cost-cutting actions come as Vical tries to eke out its cash while looking into strategic alternatives.

MorphoSys co-founder Simon Moroney announced his plans to retire from the company. He will step down as CEO after his current contract expires in June 2020, or earlier if a successor is appointed before that time.

Eli Lilly & Co. and Pfizer’s non-opioid nerve growth factor inhibitor tanezumab beat out placebo in a phase 3 study of patients with chronic lower back pain who had previously seen inadequate relief from at least three different classes of painkillers.

Arix Bioscience’s five-month search for a CEO has ended with it reappointing the person who vacated the role at the start of the process. Joe Anderson stepped down as CEO in September to take up the chief investment officer position but now finds himself back in charge of the company.

A Duke lab at the center of a research pact with Sarepta is reporting promising results from a trial of CRISPR gene editing in mouse models of DMD. But the treatment has produced some off-target effects, which the researchers plan to investigate further in future studies.

TCR2 Therapeutics has priced its IPO at the midpoint of the target range. The offering stands to net TCR2 $67 million, setting it up to move cell therapies designed to better CAR-Ts through early-phase development.

Researchers at the University of Louisville were testing a protein-based molecule they originally developed to boost the power of T cells in treating cancer when they made a surprising discovery: The drug protected normal mice from developing cancer in the first place.

Congress has approved a budget deal to avert another government shutdown. The deal, which is due to be signed into law by President Trump, includes the biggest increase in FDA funding in several years.

Sanofi's new chief digital officer joins executives looking to leverage tech; Parexel nabs four high-profile FDA staffers; and Nimbus brings on Janssen's discovery head as CSO. Those moves plus more hirings, firings and retirings throughout the industry.

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run. You may also view the following:

Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format.

View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

Show or hide the record’s caption (content description).

Show actions that can be made with the search result record.

Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.